CagriSema: The Amylin + GLP-1 Combination Research Profile

Summary

Cagrilintide (an amylin analog) combined with Semaglutide is the headline 'next-step' weekly research combination after Wegovy.

Why It Matters

Amylin signaling adds a satiety dimension that pure GLP-1 doesn't fully cover. The CagriSema research program is the highest-profile non-triple-agonist competitor.

Key Findings

• Phase 2 weight-loss readouts ranged in the 15–17% region at the studied doses.
• Side-effect profile reads as additive with Semaglutide.
• Phase 3 REDEFINE program is the read everyone is waiting on.

Related Peptides

• Cagrilintide
• Semaglutide
• Cagrilintide + Semaglutide